A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer
Status:
Terminated
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
This is an exploratory biomarker study. Patients with metastatic colorectal cancer will
receive regorafenib, which is FDA approved in this setting, on day 1-21 of every consecutive
28 day cycle. Patients will be asked to undergo tumor biopsy at baseline and 2 weeks after
starting regorafenib. Peripheral blood samples will be collected at baseline 2 weeks after
starting regorafenib, after initiation of cycle 3, and every 4 weeks thereafter.